This company listing is no longer active
RENE Stock Overview
Researches, develops, and commercializes cell-based therapies in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ReNeuron Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.034 |
| 52 Week High | UK£0.11 |
| 52 Week Low | UK£0.033 |
| Beta | 0.69 |
| 1 Month Change | 0% |
| 3 Month Change | -2.17% |
| 1 Year Change | -58.59% |
| 3 Year Change | -97.71% |
| 5 Year Change | -98.75% |
| Change since IPO | -99.87% |
Recent News & Updates
Recent updates
We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth Carefully
Jul 15
We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn Rate
Jan 22Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth
Oct 12Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?
Jun 04Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?
Jan 12
Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)
Nov 20Shareholder Returns
| RENE | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 0.5% |
| 1Y | -58.6% | -25.8% | 2.7% |
Return vs Industry: RENE underperformed the UK Biotechs industry which returned -26.8% over the past year.
Return vs Market: RENE underperformed the UK Market which returned 3% over the past year.
Price Volatility
| RENE volatility | |
|---|---|
| RENE Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: RENE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RENE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 26 | n/a | www.reneuron.com |
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells.
ReNeuron Group plc Fundamentals Summary
| RENE fundamental statistics | |
|---|---|
| Market cap | UK£1.93m |
| Earnings (TTM) | -UK£5.07m |
| Revenue (TTM) | UK£249.00k |
7.7x
P/S Ratio-0.4x
P/E RatioIs RENE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RENE income statement (TTM) | |
|---|---|
| Revenue | UK£249.00k |
| Cost of Revenue | UK£3.65m |
| Gross Profit | -UK£3.40m |
| Other Expenses | UK£1.67m |
| Earnings | -UK£5.07m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | -0.089 |
| Gross Margin | -1,367.47% |
| Net Profit Margin | -2,037.35% |
| Debt/Equity Ratio | 0% |
How did RENE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/04 14:24 |
| End of Day Share Price | 2024/02/05 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2023/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ReNeuron Group plc is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Paul St. Johnson | Allenby Capital Limited |
| Navid Malik | Cavendish Historical (Cenkos Securities) |
| Vadim Alexandre Khalil | Daniel Stewart & Company |